Precigen is trading at $8.88, up 10.37%, amid supportive broader-market sentiment after cooler-than-expected inflation boosted hopes the Fed might delay rate hikes. - Reuters reported the Nasdaq jumped more than 1%. - No new company-specific announcement dated September 30 was identified; the latest listed Precigen press release was September 21. - The FDA AdenoVerse designation and B. Riley Buy initiation were reported before September 30 and are context, not confirmed fresh catalysts.